非心源性短暂性脑缺血发作或卒中长期抗血小板治疗的获益与风险平衡
该研究汇总6项随机临床试验的个体患者数据,按S2TOP-BLEED评分将非心源性TIA或卒中患者分为预测大出血风险五分位,评估不同抗血小板方案的净获益。结果显示大出血与复发性缺血事件风险平行增加,阿司匹林联合氯吡格雷在所有五分位均增加大出血风险超过缺血事件减少,不能仅凭出血风险评估个体化抗血小板治疗。
要点
- 大出血与复发性缺血事件风险随预测出血风险五分位平行增加。
- 阿司匹林联合氯吡格雷在所有五分位增加大出血超过缺血事件减少。
- 不能仅基于出血风险评估个体化选择抗血小板治疗。
核心结论
- 在非心源性TIA或卒中患者中,复发性缺血事件与大出血风险平行增加,抗血小板治疗不能仅凭出血风险评估个体化。
主要发现
- 按S2TOP-BLEED评分五分位,阿司匹林单药治疗时大出血年风险从0.7%/年(最低五分位)增至3.2%/年(最高五分位),缺血事件年风险从2.5%/年增至10.2%/年。
- 阿司匹林联合氯吡格雷在所有五分位导致更多大出血(0.9%–1.7%/年),而缺血事件减少仅0.4%至0.9/1.0%/年。
- 根据基线出血风险,阿司匹林联合双嘧达莫与氯吡格雷之间无明确偏好。
临床怎么用
- 临床决策不能仅依据出血风险评估来个体化选择抗血小板方案,需综合评估缺血与出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Lifelong treatment with antiplatelet drugs is recommended following a transient ischemic attack or ischemic stroke. Bleeding complications may offset the benefit of antiplatelet drugs in patients at increased risk of bleeding and low risk of recurrent ischemic events. We aimed to investigate the net benefit of antiplatelet treatment according to an individuals’ bleeding risk. METHODS: We pooled individual patient data from 6 randomized clinical trials (CAPRIE [Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events], ESPS-2 [European Stroke Prevention Study-2], MATCH [Management of Atherothrombosis With Clopidogrel in High-Risk Patients], CHARISMA [Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance], ESPRIT [European/Australasian Stroke Prevention in Reversible Ischemia Trial], and PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes]) investigating antiplatelet therapy in the subacute or chronic phase after noncardioembolic transient ischemic attack or stroke. Patients were stratified into quintiles according to their predicted risk of major bleeding with the S2TOP-BLEED score. The annual risk of major bleeding and recurrent ischemic events was assessed per quintile for 4 scenarios: (1) aspirin monotherapy, (2) aspirin-clopidogrel versus aspirin or clopidogrel monotherapy, (3) aspirin-dipyridamole versus clopidogrel, and (4) aspirin versus clopidogrel. Net benefit was calculated for the second, third, and fourth scenario. RESULTS: Thirty seven thousand eighty-seven patients were included in the analyses. Both risk of major bleeding and recurrent ischemic events increased over quintiles of predicted bleeding risk, but risk of ischemic events was consistently higher (eg, from 0.7%/y (bottom quintile) to 3.2%/y (top quintile) for major bleeding on aspirin and from 2.5%/y to 10.2%/y for risk of ischemic events on aspirin). Treatment with aspirin-clopidogrel led to more major bleedings (0.9%–1.7% per year), than reduction in ischemic events (ranging from 0.4% to 0.9/1.0% per year) across all quintiles. There was no clear preference for either aspirin-dipyridamole or clopidogrel according to baseline bleeding risk. CONCLUSIONS: Among patients with a transient ischemic attack or ischemic stroke included in clinical trials of antiplatelet therapy, the risk of recurrent ischemic events and of major bleeding increase in parallel. Antiplatelet treatment cannot be individualized solely based on bleeding risk assessment.
引用
- Hilkens NA, Algra A, Diener HC, et al. Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. Stroke. 2021. PMID: 34304604. doi:10.1161/STROKEAHA.120.031755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。